Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Cancer

Volumn 118, Issue 4, 2012, Pages 1130-1137

  Gupta, Abha A ^a   Anderson, James R ^b   Pappo, Alberto S ^c   Spunt, Sheri L ^c   Dasgupta, Roshni ^d   Indelicato, Daniel J ^e   Hawkins, Douglas S ^f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

adolescent; age; chemotherapy; rhabdomyosarcoma; sex; toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGE; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; AGE DISTRIBUTION; BLOOD TOXICITY; DISEASE ASSOCIATION; INCIDENCE; INFECTION RATE; NEUROTOXICITY; TREATMENT RESPONSE;

ADOLESCENT; AGE FACTORS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; IFOSFAMIDE; INCIDENCE; MALE; MESNA; NEUTROPENIA; RHABDOMYOSARCOMA; SEX CHARACTERISTICS; SURVIVAL RATE; THROMBOCYTOPENIA; VINCRISTINE; YOUNG ADULT;

EID: 84856785909     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26358     Document Type: Article

References (38)

1. Pappo AS, Shapiro DN, Crist WM, Maurer HM,. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. 1995; 13: 2123-2139.
2. Crist WM, Kun LE,. Common solid tumors of childhood. N Engl J Med. 1991; 324: 461-471.
3. Heyn RM, Holland R, Newton WA Jr, Tefft M, Breslow N, Hartmann JR,. The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer. 1974; 34: 2128-2142.
4. Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001; 19: 3091-3102.
5. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W,. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2004; 42: 64-73.
6. Orbach D, Rey A, Oberlin O, et al. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol. 2005; 23: 4363-4371.
7. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A,. Comparing adult and pediatric rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009; 27: 3391-3397.
8. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B,. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008; 8: 288-298.
9. Bleyer A,. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007; 57: 242-255.
10. Veal GJ, Hartford CM, Stewart CF,. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol. 2010; 28: 4790-4799.
11. Kaplan EL MP,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 1-39.
13. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006; 47: 22-29.
14. Khamly KK, Thursfield VJ, Fay M, et al. Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer. 2009; 125: 426-431.
15. Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005; 23: 8003-8011.
16. Mayers C, Panzarella T, Tannock IF,. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 2001; 91: 2246-2257.
17. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995; 13: 610-630.
18. Baker KS, Anderson JR, Link MP, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2000; 18: 2427-2434.
19. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group study D9803. J Clin Oncol. 2009; 27: 5182-5188.
20. Ortega JA, Donaldson SS, Ivy SP, Pappo A, Maurer HM,. Veno-occlusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer. 1997; 79: 2435-2439.
21. Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W,. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol. 2004; 22: 1894-1901.
22. Spunt SL, Smith LM, Ruymann FB, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin Cancer Res. 2004; 10 (18 pt 1): 6072-6079.
23. Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009; 27: 1446-1455.
24. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009; 27: 2536-2541.
25. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH,. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005; 44: 1135-1164.
26. McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR,. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. J Clin Pharmacol. 2009; 49: 88-102.
27. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007; 13: 853-862.
28. McCune JS, Batchelder A, Guthrie KA, et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther. 2009; 85: 615-622.
29. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcomaâa report from the IRSG. Int J Radiat Oncol Biol Phys. 2001; 51: 718-728.
30. Tomlinson D, Gibson F, Treister N, et al. Challenges of mucositis assessment in children: expert opinion. Eur J Oncol Nurs. 2008; 12: 469-475.
31. Tomlinson D, Judd P, Hendershot E, Maloney AM, Sung L,. Measurement of oral mucositis in children: a review of the literature. Support Care Cancer. 2007; 15: 1251-1258.
32. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH,. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998; 338: 499-505.
33. Madden T, Bleyer WA, Hohnecker J, et al. The pharmacokinetics of vinorelbine in pediatric cancer patients [abstract]. Proc Am Soc Clin Oncol. 1995; 14: 168.
34. Frost BM, Lonnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr. 2003; 92: 551-557.
35. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007; 49: 928-940.
36. Donaldson SS, Anderson JR,. Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol. 2005; 23: 2586-2587.
37. Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric OncologyâSIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005; 23: 2618-2628.
38. Langholz B, Skolnik JM, Barrett JS, et al. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. Pediatr Blood Cancer. 2011; 57: 252-257.